IR-Med, Inc. Appoints Yaniv Cohen as Interim CEO and Board Member

What Happened IR-Med, Inc. filed an 8-K (Item 5.02) on Sept 15, 2026 announcing that its Board appointed Yaniv Cohen as interim Chief Executive Officer and added him to the Board, effective Sept 14, 2026. Mr. Cohen co-founded IR. Med Ltd. in 2013, became the company’s Chief Scientific Officer after IR-Med’s acquisition of IR. Med Ltd., and previously served as R&D manager.

Key Details

• Appointment effective date: September 14, 2026; 8-K filed Sept 15, 2026 (Item 5.02).
• appointee: Yaniv Cohen, age 46 — co-founder of IR. Med Ltd.; currently CSO following the acquisition.
• Background: electrical engineer with expertise in wave propagation and IR spectroscopy; holds four medical-device patents, co-authored eight journal articles, and holds a Ph.D. (MIEM HSE, Moscow) and an M.Sc. (Holon Institute of Technology). Prior roles include R&D manager at PIMS, system engineer at Cisco, and service engineer at Intel Israel.
• Compensation/arrangements: Company has not entered into any new or amended compensatory agreements with Mr. Cohen; he will continue to participate in standard non-employee director compensation programs, if applicable. No related-party transactions requiring Item 404(a) disclosure were reported.

Why It Matters This is an executive leadership change: an interim CEO and board member with technical and operational experience in the company’s core medical IR technology has been installed. For investors, the appointment signals continuity of technical leadership (C-suite and board) following the acquisition of IR. Med Ltd., and the company has not yet agreed to any new compensation terms for the interim CEO.